drugset
drugset / Trial / NCT02256033

Effect of Mild Hepatic Impairment on the Pharmacokinetics of Istradefylline

NCT02256033 ↗

Phase 1 Completed 20 enrolled Kyowa Kirin, Inc. Kyowa Hakko Kirin Pharma, Inc. · collab
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to test whether mild liver impairment affects blood levels of istradefylline in humans. Decreased liver function could possibly increase istradefylline levels.

Timeline

Start
2014-08
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Istradefylline Small molecule 40 mg —

Indications

No indication recorded.